FDA warned Blue Horizon International over unapproved stem cell and exosome biologics marketed for serious diseases without a license.
What happened
FDA reviewed the company’s website in May 2026 and found it marketed umbilical cord blood stem cell therapy and Wharton’s Jelly exosome therapy for diseases such as multiple sclerosis, rheumatoid arthritis, cardiovascular disease, and diabetes. FDA said the products are drugs and biological products, lack an approved biologics license or investigational new drug application, and are misbranded because they lack adequate directions for use.
What FDA found
FDA says the website claims the products treat many diseases, making them drugs and biological products.
FD&C Act § 201(g)(1); PHS Act § 351(i)FDA says the umbilical cord blood product is not intended for homologous use, so it is not regulated only as a tissue product.
21 CFR 1271.10(a)(2); 21 CFR 1271.3(c)FDA says the cord blood product is allogeneic, depends on living cells, and is not for autologous, close-relative, or reproductive use.
21 CFR 1271.10(a)(4)FDA says the company has no approved biologics license or investigational new drug application for either product.
42 U.S.C. § 262(a); 21 U.S.C. § 355(i); 21 CFR Part 312FDA says the products are misbranded because they lack adequate directions for use by a layperson.
FD&C Act § 502(f)(1), 21 U.S.C. § 352(f)(1); 21 CFR 201.5FDA says holding misbranded products for sale after interstate shipment violates the law.
FD&C Act § 301(k), 21 U.S.C. § 331(k)
What FDA wants
FDA asks the company to respond in writing within 15 working days with specific steps taken or planned to correct the violations and prevent recurrence, plus supporting documentation. If more time is needed, the company must explain the delay and give a completion timeframe.
Who should pay attention
- clinics and patients considering stem cell or exosome therapy
- companies marketing unapproved biologic products
- suppliers or distributors of cord blood and WJ-MSC products
This is a summary. Read the original letter on fda.gov.